These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20032541)

  • 1. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
    Wilson SS; Cheshenko N; Fakioglu E; Mesquita PM; Keller MJ; Herold BC
    Antivir Ther; 2009; 14(8):1113-24. PubMed ID: 20032541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
    Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
    Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
    Segarra TJ; Fakioglu E; Cheshenko N; Wilson SS; Mesquita PM; Doncel GF; Herold BC
    PLoS One; 2011; 6(11):e27675. PubMed ID: 22096611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety.
    Galen BT; Martin AP; Hazrati E; Garin A; Guzman E; Wilson SS; Porter DD; Lira SA; Keller MJ; Herold BC
    J Infect Dis; 2007 May; 195(9):1332-9. PubMed ID: 17397004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
    Shankar GN; Alt C
    J Antimicrob Chemother; 2014 Dec; 69(12):3282-93. PubMed ID: 25139839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
    Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
    N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
    Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.
    Andrei G; Lisco A; Vanpouille C; Introini A; Balestra E; van den Oord J; Cihlar T; Perno CF; Snoeck R; Margolis L; Balzarini J
    Cell Host Microbe; 2011 Oct; 10(4):379-89. PubMed ID: 22018238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
    Friend DR
    Expert Opin Drug Deliv; 2012 Apr; 9(4):417-27. PubMed ID: 22385316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
    Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.
    Fernández-Romero JA; Abraham CJ; Rodriguez A; Kizima L; Jean-Pierre N; Menon R; Begay O; Seidor S; Ford BE; Gil PI; Peters J; Katz D; Robbiani M; Zydowsky TM
    Antimicrob Agents Chemother; 2012 Jan; 56(1):358-68. PubMed ID: 22064530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
    Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC
    PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.
    Bender Ignacio RA; Perti T; Magaret AS; Rajagopal S; Stevens CE; Huang ML; Selke S; Johnston C; Marrazzo J; Wald A
    J Infect Dis; 2015 Dec; 212(12):1949-56. PubMed ID: 26044291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.
    Cone RA; Hoen T; Wong X; Abusuwwa R; Anderson DJ; Moench TR
    BMC Infect Dis; 2006 Jun; 6():90. PubMed ID: 16740164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
    Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
    Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
    Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
    J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.
    Mesquita PM; Cheshenko N; Wilson SS; Mhatre M; Guzman E; Fakioglu E; Keller MJ; Herold BC
    J Infect Dis; 2009 Aug; 200(4):599-608. PubMed ID: 19586414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.